The S&P 500 soared more than 32% in 2013, and several big pharma companies, namely Bristol-Myers Squibb (BMY -1.96%), AbbVie (ABBV -0.78%), Roche (RHHBY -2.12%), Johnson & Johnson (JNJ 0.92%), and AstraZeneca (AZN -2.77%) also performed extraordinarily well. The following slideshow reveals why these companies beat out their big pharma peers and what drove their strong performances in 2013.
Free Article
The 5 Best-Performing Big Pharma Stocks of 2013: BMY, ABBV, RHHBY, JNJ, AZN
By Max Macaluso
–
Jan 6, 2014 at 6:30PM
The pharmaceutical sector had a stellar 2013, but which stocks were the best?
Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences, ImmunoGen, and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Johnson & Johnson
JNJ
$164.92
(0.92%)
$1.50
Bristol-Myers Squibb
BMY
$71.23
(-1.96%)
$-1.42
Roche Ag
RHHBY
$38.32
(-2.12%)
$0.83
AstraZeneca Plc
AZN
$63.56
(-2.77%)
$-1.81
AbbVie
ABBV
$146.60
(-0.78%)
$-1.15
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Align Technology (ALGN) Q4 2022 Earnings Call Transcript
Why Humana Stock Lagged the Market Today
Why Amgen Stock Wilted on Wednesday
Novo Nordisk A/s (NVO) Q4 2022 Earnings Call Transcript
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
401%
Our Most Popular Articles
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.